Major Big Pharma companies have abruptly halted their latest COVID-19 mRNA “booster” trial because they literally couldn’t find enough willing participants.
After years of gaslighting the American public, raking in hundreds of billions in profits from experimental shots that were shoved down our throats under the guise of “public health,” the same corporations that partnered with the Biden regime, Anthony Fauci, and the lying mainstream media are now facing the cold, hard reality: Americans are done being lab rats.
According to internal letters sent to trial investigators and obtained by Reuters, Pfizer is ending its study of “updated” shots in healthy adults aged 50 to 64.
The company admitted it was “unable to generate relevant data” because recruitment had effectively hit a brick wall.
Reports indicate that more than 80% of potential recruits didn’t even make it past pre-screening, or simply refused to participate.
The trial, which aimed to enroll a massive 25,000 to 30,000 participants, folded after failing to meet even the most basic enrollment targets.
This comes at a time when the “science” is being scrutinized like never before. Under the current administration, the FDA has been pressured to actually require randomized placebo-controlled trials, the very thing skeptics have been demanding for years.
It seems that when Big Pharma actually has to play by the rules and prove efficacy to a skeptical public, they simply can’t find the “volunteers” anymore.
Pfizer isn’t the only one feeling the heat. Moderna is reportedly facing similar “recruitment challenges” for its own 30,000-person study.
Pfizer and BioNTech told Reuters they are halting the study because slow enrollment is preventing them from generating relevant post-marketing data on the vaccine. “This is a very difficult population to recruit,” an unnamed executive at a contract research organization involved in the trial added on the condition of anonymity. People with chronic conditions such as hypertension or diabetes were ineligible for the study.
“Even when patients are willing to participate in COVID studies, more than 80% fail at prescreening because they don’t meet the health criteria,” the executive told Reuters. “It’s been a real challenge to enroll enough patients, particularly given the scale of these trials.”
The news comes after the FDA imposed new requirements on COVID-19 vaccines last year. In May, the agency announced it would require data from placebo-controlled trials to inform decisions about whether to support the use of COVID-19 vaccines in people aged 50 to 64. Neither Pfizer and BioNTech’s Comirnaty nor Moderna’s Spikevax and next generation mNEXSPIKE has full approval in this age group.
Moderna is also running a COVID-19 vaccine trial in people aged 50 to 64. Sources at four sites involved in the study told Reuters that the company is also facing enrollment challenges. Moderna has yet to comment on the trial’s enrollment rate, although commercial challenges in the U.S. vaccine market could suggest a dip in the number of people interested in the trial.
Jim Hᴏft is the founder and editor of The Gateway Pundit, one of the top conservative news outlets in America. Jim was awarded the Reed Irvine Accuracy in Media Award in 2013 and is the proud recipient of the Breitbart Award for Excellence in Online Journalism from the Americans for Prosperity Foundation in May 2016.
You can email Jim Hᴏft here, and read more of Jim Hᴏft’s articles here.
Ad block users: Some site features may not work correctly while an ad blocker is enabled, because they break scripts and content this website depends on. If you can’t see comments below, for example, please disable your ad blocker.
